VALBIOTIS (EPA:ALVAL)

BRIEF

published on 04/03/2024 at 08:35, 7 months 20 days ago

Valbiotis launches an innovative food supplement to fight hypercholesterolemia

Valbiotis Cardiovascular Health Lipidrive Hypercholesterolemia Dietary Supplement
PRESS RELEASE

published on 04/03/2024 at 08:30, 7 months 20 days ago

Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May
Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May. The supplement, Valbiotis®PRO Cholestérol, with the patented active substance Lipidrive®, aims at tackling mild to moderate LDL hypercholesterolemia

Valbiotis French Market Lipidrive Hypercholesterolemia Dietary Supplement
BRIEF

published on 03/07/2024 at 17:45, 8 months 15 days ago

VALBIOTIS SA announces its voting rights figures for February 2024

Share Capital Voting Rights Transparency Valbiotis Financial Market
PRESS RELEASE

published on 01/29/2024 at 17:40, 9 months 24 days ago

Valbiotis presents its 2024 financial communication calendar
Valbiotis presents its 2024 financial communication calendar. The company specializing in dietary supplements announces publication dates for the 2023 annual report and 2024 half-year report, as well as the Annual General Meeting

Financial Communication Calendar Valbiotis Dietary Supplements Metabolic Diseases Cardiovascular Diseases
PRESS RELEASE

published on 11/07/2023 at 17:40, 1 year ago

Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes
PRESS RELEASE

published on 10/02/2023 at 17:40, 1 year 1 month ago

VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes
PRESS RELEASE

published on 09/28/2023 at 17:40, 1 year 1 month ago

Valbiotis publishes its financial report for the first half of 2023 and confirms its strategic roadmap
PRESS RELEASE

published on 09/11/2023 at 17:40, 1 year 2 months ago

VALBIOTIS SA: Valbiotis presents the full results of the Phase II/III REVERSE-IT study: impressive efficacy of TOTUM•63 against prediabetes and the early stages of type 2 diabetes
PRESS RELEASE

published on 07/12/2023 at 17:40, 1 year 4 months ago

Valbiotis announces its roadmap and strategic priorities on the eve of key milestones for its portfolio of innovative active substances
PRESS RELEASE

published on 07/03/2023 at 17:40, 1 year 4 months ago

Valbiotis announces the appointment of Charlotte JEZEQUEL as Director of Human Relations and Executive Committee member

Published on 11/22/2024 at 23:55, 9 hours 29 minutes ago

Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 9 hours 54 minutes ago

Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 10 hours 19 minutes ago

Kidoz Inc. Announces Results of 2024 AGM
Published on 11/22/2024 at 23:05, 10 hours 19 minutes ago

Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 10 hours 54 minutes ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 15 hours 9 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 15 hours 24 minutes ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 15 hours 31 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 16 hours 28 minutes ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 17 hours 24 minutes ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 14:35, 18 hours 49 minutes ago

Thales Press release
Published on 11/21/2024 at 06:58, 2 days 2 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 2 days 14 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 2 days 15 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 2 days 15 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024

View all LES ECHOS COMFI WIRE

News